DIFFERIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIFFERIN (DIFFERIN).
Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.
| Metabolism | Adapalene is minimally metabolized in the skin; systemic absorption is low. Any absorbed drug is primarily metabolized in the liver via cytochrome P450 enzymes, likely CYP2C9 and CYP3A4, and excreted in bile as metabolites. |
| Excretion | Primarily biliary/fecal (>95%) as unchanged drug and metabolites; renal excretion is negligible. |
| Half-life | Terminal elimination half-life is approximately 14–22 hours; steady-state is achieved within 3–5 days. |
| Protein binding | Highly protein-bound (>99%), mainly to plasma albumin and lipoproteins. |
| Volume of Distribution | Large volume of distribution (~14–16 L/kg), indicating extensive tissue binding and distribution. |
| Bioavailability | Topical absorption is minimal (<5% of applied dose); systemic bioavailability is negligible. |
| Onset of Action | Clinical effect on acne lesions is evident after 4–8 weeks of topical application. |
| Duration of Action | Sustained improvement in acne lesions with continued use; effects persist for weeks after discontinuation. |
| Molecular Weight | 412.52 |
Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Approved for acne vulgaris in patients aged 12 years and older: apply 0.1% gel or cream once daily. Safety and efficacy in children under 12 not established. |
| Geriatric use | No specific dose adjustment; use with caution due to increased risk of skin irritation and dryness in elderly skin. |
| 1st trimester | Topical adapalene is not recommended during the first trimester due to lack of adequate human data and potential risk from retinoids. Animal studies suggest a risk, but human data are limited. |
| 2nd trimester | Topical adapalene should be used during the second trimester only if potential benefit justifies potential risk to the fetus. Limited human data do not indicate a major risk, but caution is warranted. |
| 3rd trimester | Topical adapalene is not recommended in the third trimester as a precaution due to theoretical risk of retinoid effects, although absorption is minimal. |
Clinical note
Comprehensive clinical and safety monograph for DIFFERIN (DIFFERIN).
| Placental transfer | Minimal placental transfer is expected due to low systemic absorption after topical application. No specific data on adapalene placental transfer; however, given low bioavailability, systemic levels are negligible. |
| Breastfeeding |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to adapalene or any component of the formulation
| Precautions | Avoid application to cuts, abrasions, eczematous, or sunburned skin., Avoid excessive exposure to sunlight and UV light; use sunscreen., Possible local skin reactions: erythema, scaling, dryness, burning, pruritus; dose reduction or interruption may be necessary., Use caution in patients with eczema., Not for oral or ophthalmic use. |
| Food/Dietary | No significant food interactions. However, high-fat meals may slightly increase systemic absorption; unlikely to be clinically relevant. |
| Clinical Pearls |
Loading safety data…
| Topical adapalene is likely compatible with breastfeeding due to low systemic absorption (<4% of applied dose). Avoid application to the breast area to prevent infant ingestion. Use caution if applying to large areas or under occlusion. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/third trimester: limited data, avoid use. No adequate human studies. |
| Fetal Monitoring | No specific monitoring required for topical use. Inadvertent oral overdose: monitor fetal development via ultrasound. Avoid use during pregnancy; if exposed, confirm gestational age and assess for fetal anomalies. |
| Fertility Effects | No known effects on fertility in humans. Animal studies at high oral doses showed impaired fertility; topical use unlikely to impact fertility due to minimal absorption. |
| Use a pea-sized amount for entire face to avoid irritation. Initiate with lower concentration (0.1% gel) for sensitive skin. Combination with benzoyl peroxide or topical antibiotics may enhance efficacy. Sunscreen is mandatory due to photosensitization. Do not apply to broken, eczematous, or sunburned skin. |
| Patient Advice | Apply a thin layer once daily at bedtime to clean, dry skin. · Avoid excessive washing or using abrasive cleansers. · Use oil-free, non-comedogenic moisturizers and cosmetics. · Expect initial worsening of acne (retinoid reaction) which resolves in 4-6 weeks. · Sun protection (SPF 30+) and protective clothing are essential daily. · Minimize exposure to extreme wind or cold. · If pregnant, planning pregnancy, or breastfeeding, consult physician before use. · Keep away from eyes, mouth, nasal angles, and mucous membranes. |